Business Context and Reporting Period
Company: Pfizer Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 28, 2004
Context: The quarter reflects the full impact of the April 2003 acquisition of Pharmacia Corporation. Pfizer also completed the acquisition of Esperion Therapeutics, Inc. in February 2004. The company is actively restructuring operations to integrate Pharmacia and divesting non-core businesses, which are reported as discontinued operations.
Key Financial Metrics
| Metric (in millions) | Q1 2004 | Q1 2003 |
|---|---|---|
| Revenues | $12,487 | $8,506 |
| Net Income | $2,331 | $4,665 |
| Income from Continuing Operations | $2,318 | $2,455 |
| Diluted EPS (Net Income) | $0.30 | $0.76 |
| Operating Cash Flow | $1,583 | $2,323 |
| Total Debt | $17,836 | $14,573 |
| Cash & Short-term Investments | $13,952 | $11,952 |
| Working Capital | $10,752 | $6,768 |
Note: Q1 2003 Net Income included $2,202 million in gains from discontinued operations (sales of Adams, Schick, and women's health products), which are not present in Q1 2004.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 47% year-over-year, driven primarily by the inclusion of Pharmacia products, strong performance of key drugs (Lipitor, Zoloft, Celebrex), and favorable foreign exchange rates.
- Profitability Decline: Reported Net Income decreased 50% primarily due to the absence of the $2.2 billion gain on discontinued operations recorded in Q1 2003. Income from continuing operations decreased slightly (6%) due to significant merger-related charges.
- Merger Charges: Pfizer recorded $955 million in merger-related in-process research and development (IPR&D) charges (primarily for the Esperion acquisition) and $247 million in other merger-related costs.
- Discontinued Operations: Q1 2004 reported only $13 million from discontinued operations compared to $2,240 million in Q1 2003. Pfizer decided to sell its Diagnostics, surgical ophthalmic, and certain European generic/consumer businesses.
- Debt Levels: Total debt increased by approximately $3.3 billion, reflecting new issuances of $1.45 billion in senior unsecured notes in February 2004.
Guidance, Outlook, and Risks
Management Outlook
- 2004 Revenue Target: Approximately $54 billion.
- 2004 Adjusted Income: $16.3 billion (Adjusted Diluted EPS of $2.13).
- 2004 Reported Net Income: Projected at $11.9 billion (Reported Diluted EPS of $1.55).
- R&D Spend: Planned at approximately $7.9 billion for 2004.
Risks and Contingencies
- Patent Expirations: Key products face patent expirations or generic competition, including Diflucan (patent expired Jan 2004, pediatric exclusivity through July 2004), Viagra, and Zithromax.
- Legal Proceedings: Significant pending litigation includes patent challenges for Xalatan and Detrol, and approximately 305,000 asbestos-related claims pending against Pfizer and subsidiaries.
- Regulatory: Risks associated with FDA approvals for new products (e.g., Exubera, Daxas) and potential legislative changes affecting pharmaceutical pricing and reimbursement.
Investor Verification Checklist
- Adjusted vs. Reported Earnings: Verify the reconciliation between Reported Net Income ($2.33B) and Adjusted Income ($3.98B) to understand the impact of non-cash purchase accounting and merger costs.
- Discontinued Operations: Confirm the status and expected closing dates for the divestitures of the Diagnostics ($575M) and surgical ophthalmic ($450M) businesses.
- Patent Litigation Outcomes: Monitor the trial results for Xalatan (latanoprost) and the appeal regarding Diflucan pediatric exclusivity, as these directly impact future revenue streams.
- Merger Integration Costs: Track the realization of projected $3.4 billion in cost synergies for 2004 against the $6.0 billion total expected merger expenditures through 2005.
- Debt Servicing: Review the impact of the new $1.45 billion debt issuance on future interest expenses and cash flow.